Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosyngen Nabs US Fast Track Status for TIL Cell Therapy in Liver Cancer

publication date: Feb 2, 2024

Biosyngen, a Singapore-Guangzhou cell therapy company, was granted US Fast Track designation for BST02, a clinical stage tumor-infiltrating lymphocyte (TIL), for liver cancer indications, including hepatocellular carcinoma and cholangiocarcinoma. In October 2023, BST02 was approved to start a US Phase I/II clinical trial. China issued a similar approval in January 2024. BST02 is the first TIL cell therapy drug for liver cancer to advance into a clinical trial globally. Another product from Biosyngen, BRG01, was granted fast track designation in July 2023. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital